Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MBOT Stock Forecast 2025-2026
$2.47
Current Price
$88.03M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MBOT Price Targets
+264.4%
To High Target of $9.00
+264.4%
To Median Target of $9.00
+264.4%
To Low Target of $9.00
MBOT Price Momentum
-0.4%
1 Week Change
-9.9%
1 Month Change
+142.2%
1 Year Change
+120.5%
Year-to-Date Change
-26.9%
From 52W High of $3.38
+201.2%
From 52W Low of $0.82
📊 TOP ANALYST CALLS
Did MBOT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Microbot is one of their latest high-conviction picks.
Latest MBOT Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, MBOT has a bullish consensus with a median price target of $9.00 (ranging from $9.00 to $9.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.47, the median forecast implies a 264.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 264.4% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 264.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MBOT Analyst Ratings
1
Buy
0
Hold
0
Sell
MBOT Price Target Range
Low
$9.00
Average
$9.00
High
$9.00
Current: $2.47
Latest MBOT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MBOT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| Jan 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $9.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $7.00 |
| Apr 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Oct 18, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $8.00 |
| Jun 26, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $8.00 |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 9, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $8.00 |
| Nov 25, 2020 | Ladenburg Thalmann | Neutral | Downgrade | $0.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Nov 25, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Aug 18, 2020 | HC Wainwright & Co. | Buy | Maintains | $20.00 | |
| Jan 13, 2020 | HC Wainwright & Co. | Buy | Reiterates | $26.00 | |
| Jan 13, 2020 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Dec 24, 2019 | HC Wainwright & Co. | Buy | Reiterates | $12.00 | |
| Dec 24, 2019 | H.C. Wainwright | Buy | Reiterates | $0.00 | |
| Jul 22, 2019 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| Jul 22, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Nov 19, 2018 | Ladenburg Thalmann | Neutral | Downgrade | $0.00 | |
| Jan 31, 2018 | Ladenburg Thalmann | Buy | Initiates | $0.00 |
Microbot Medical Inc. (MBOT) Competitors
The following stocks are similar to Microbot based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MBOT
Microbot Medical
mkt cap
85.12M
Microbot Medical Inc. (MBOT) Financial Data
Microbot Medical Inc. has a market capitalization of $88.03M with a P/E ratio of -3.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -66.5%.
Valuation Metrics
Market Cap
$88.03M
Enterprise Value
$57.78M
P/E Ratio
-3.4x
PEG Ratio
-4.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+33.8%
Current Ratio
16.2x
Debt/Equity
0.5x
ROE
-66.5%
ROA
-40.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Microbot Medical Inc. (MBOT) Business Model
About Microbot Medical Inc.
What They Do
Develops micro-robotic medical solutions.
Business Model
The company focuses on creating innovative micro-robotic devices that enhance minimally invasive surgeries and medical procedures. By addressing the demand for precision and efficacy, Microbot Medical generates revenue through the sale of these advanced medical devices to healthcare providers and institutions.
Additional Information
Headquartered in Massachusetts, Microbot Medical is at the forefront of robotic technology for endoluminal procedures, navigating through natural body lumens. Its advancements aim to improve surgical practices and patient care, aligning with healthcare providers' priorities for reducing recovery times and enhancing procedural accuracy.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
20
CEO
Mr. Harel Gadot
Country
United States
IPO Year
1992
Website
microbotmedical.comMicrobot Medical Inc. (MBOT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Jun 12, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) has secured a crucial patent for its LIBERTY Endovascular Robotic System in China, advancing its global intellectual property strategy.
Why It Matters
Microbot Medical's patent grant in China enhances its competitive edge, potentially increasing market access and revenue, which can boost stock performance and attract investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical (MBOT) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.
Why It Matters
Microbot Medical's upgrade to a Zacks Rank #2 indicates increased market confidence in its earnings potential, suggesting potential stock price appreciation and investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) is expanding its commercial team ahead of the anticipated U.S. launch of the LIBERTY Endovascular Robotic System in Q3 2025.
Why It Matters
Microbot Medical's expansion of its commercial team signals readiness for the LIBERTY System launch, potentially boosting revenue and stock performance as it enters the market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. (Nasdaq: MBOT) will be included in the preliminary list for the Russell Microcap® Index, effective June 30, 2025, following the index reconstitution.
Why It Matters
Inclusion in the Russell Microcap® Index can boost Microbot Medical Inc.'s visibility, potentially attracting more institutional investors and increasing stock liquidity.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
1 month ago
Quick Summary
The company has hired a new VP of Marketing, joining the recently appointed VP of Sales to enhance its commercialization readiness infrastructure.
Why It Matters
The new VP of Marketing alongside the VP of Sales signals enhanced commercialization efforts, potentially boosting revenue growth and increasing investor confidence in the company's strategy.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Microbot Medical Inc. reported successful robotic navigation in its LIBERTY® Endovascular Robotic System trial, achieving a 92% reduction in radiation exposure with no adverse events.
Why It Matters
The successful results of Microbot Medical's LIBERTY® system, showing a 92% reduction in radiation exposure, could enhance its market position and attract investor interest in innovative medical technologies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MBOT Stock
What is Microbot Medical Inc.'s (MBOT) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Microbot Medical Inc. (MBOT) has a median price target of $9.00. The highest price target is $9.00 and the lowest is $9.00.
Is MBOT stock a good investment in 2025?
According to current analyst ratings, MBOT has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MBOT stock?
Wall Street analysts predict MBOT stock could reach $9.00 in the next 12 months. This represents a 264.4% increase from the current price of $2.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Microbot Medical Inc.'s business model?
The company focuses on creating innovative micro-robotic devices that enhance minimally invasive surgeries and medical procedures. By addressing the demand for precision and efficacy, Microbot Medical generates revenue through the sale of these advanced medical devices to healthcare providers and institutions.
What is the highest forecasted price for MBOT Microbot Medical Inc.?
The highest price target for MBOT is $9.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 264.4% increase from the current price of $2.47.
What is the lowest forecasted price for MBOT Microbot Medical Inc.?
The lowest price target for MBOT is $9.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 264.4% increase from the current price of $2.47.
What is the overall MBOT consensus from analysts for Microbot Medical Inc.?
The overall analyst consensus for MBOT is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are MBOT stock price projections?
Stock price projections, including those for Microbot Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 7:20 AM UTC